Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy.

Because the primary endpoint did not reach statistical significance, formal testing of secondary endpoints was not performed.

also in 111,027 other papers

Surprisingly, rates of DAS28-CRP LDA were statistically significant between etanercept and placebo at week 8, but failed to reach significance at week 12.

also in 4,113 other papers